The crystallization of monosodium urate

Current Rheumatology Reports

Volumn 16, Issue 2, 2014, Pages

  Martillo, Miguel A ^a,b   Nazzal, Lama ^a,b   Crittenden, Daria B ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Harbor Health Care System   (United States)

^c NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Crystallization; Gout; Kidney stones; Monosodium urate; Synovial fluid; Uric acid

Indexed keywords

PHOSPHOLIPID; PURINE; SODIUM ION; URATE; URIC ACID;

ARTICLE; CHONDROPATHY; CRYSTAL STRUCTURE; CRYSTALLIZATION; GOUT; HUMAN; HUMORAL IMMUNITY; HYPERURICEMIA; IMMUNOMODULATION; MECHANICAL STRESS; NEPHROLITHIASIS; PATHOGENESIS; PH; PHOSPHOLIPID MEMBRANE; PHYSICAL CHEMISTRY; PRECIPITATION; PURINE METABOLISM; RISK FACTOR; SERUM FACTOR; SOFT TISSUE INFLAMMATION; SYNOVIAL FLUID; TEMPERATURE SENSITIVITY; URIC ACID BLOOD LEVEL; URIC ACID STONE; ARTICULAR CARTILAGE; CHEMISTRY; IMMUNOLOGY; METABOLISM; REVIEW;

CARTILAGE, ARTICULAR; CHEMISTRY, PHYSICAL; CRYSTALLIZATION; GOUT; HUMANS; HYPERURICEMIA; IMMUNITY, HUMORAL; KIDNEY CALCULI; SYNOVIAL FLUID; URIC ACID;

EID: 84896707900     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0400-9     Document Type: Article

References (62)

1. Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Part II. Arthritis Rheum. 2008;58(1):26-35.
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):21.
3. Choi HK et al. Pathogenesis of gout. Ann InternMed. 2005;143(7): 499-516.
4. Burns CM, Wortmann RL. Disorders of purine and pyramidine metabolism. In: Fauci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's Priciples of Internal Medicine. New York: McGraw-Hill; 2012.
5. Wu XW et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34(1): 78-84.
6. Wu XW et al. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A. 1989;86(23):9412-6.
7. Oda M et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19(5):640-53.
8. HuangHYet al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005;52(6):1843-7.
9. Sebesta I. Genetic disorders resulting in hyper- or hypouricemia. Adv Chronic Kidney Dis. 2012;19(6):398-403.
10. Busso N, So A. Microcrystals as DAMPs and their role in joint inflammation. Rheumatology (Oxford). 2012;51(7):1154-60.
11. Martinon F et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
12. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986;83(22):8749-53.
13. Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med. 1979;91(1):56-7.
14. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
15. Hall AP et al. Epidemiology of gout and hyperuricemia. A longterm population study. Am J Med. 1967;42(1):27-37.
16. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287-9.
17. MandelNS, Mandel GS.Monosodiumurate monohydrate, the gout culprit. J Am Chem Soc. 1976;98(8):2319-23.
18. Frincu MC, Fogarty CE, Swift JA. Epitaxial relationships between uric acid crystals and mineral surfaces: a factor in urinary stone formation. Langmuir. 2004;20(16):6524-9.
19. Perrin CM et al.Monosodium urate monohydrate crystallization. CrystEngComm. 2011;13(4):1111-7.
20. Ortiz-Bravo E, Sieck MS, Schumacher Jr HR. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993;36(9):1274-85.
21. Cherian PV, Schumacher Jr HR. Immunochemical and ultrastructural characterization of serum proteins associated with monosodium urate crystals (MSU) in synovial fluid cells from patients with gout. Ultrastruct Pathol. 1986;10(3):209-19.
22. Kozin F, McCarty DJ. Molecular orientation of immunoglobulin G adsorbed to microcrystalline monosodium urate monohydrate. J Lab Clin Med. 1980;95(1):49-58.
23. Terkeltaub R et al. Plasma protein binding by monosodium urate crystals. Analysis by two-dimensional gel electrophoresis. Arthritis Rheum. 1983;26(6):775-83.
24. Mullin JW. Nucleation In Crystallization. Oxford: Butterworth- Heinemann; 1993. p. 172-201.
25. Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42 Suppl 1:12-5.
26. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-5.
27. Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. Arthritis Rheum. 1965;8(6):1123-33.
28. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189-92.
29. Wilcox WR et al. Solubility of uric acid and monosodium urate. Med Biol Eng. 1972;10(4):522-31.
30. WilcoxWR, Khalaf AA. Nucleation of monosodium urate crystals. Ann Rheum Dis. 1975;34(4):332-9.
31. Seegmiller JE. The acute attack of gouty arthritis. Arthritis Rheum. 1965;8(5):714-25.
32. Abrams B. Sleep apnea as a cause of gout flares. Medscape J Med. 2009;11(1):3.
33. McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis. 1991;50(8): 558-61.
34. Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monosodium urate at 37 degrees c. Arthritis Rheum. 1980;23(5): 574-80.
35. Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis. 1986;45(10):858-64.
36. Laurent TC. Solubility of Sodium Urate in the Presence of Chondroitin-4-Sulphate. Nature. 1964;202:1334.
37. Pascual E, Martinez A, Ordonez S. Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts. Joint Bone Spine. 2013;80(1):1-4. A recent review that summarizes information gleaned from current imaging of gouty joints, and a hypothesis regarding what this may teach us about monosodium urate crystallization.
38. Katz WA. Role of proteoglycans in the development of gouty arthritis. In: Weiner IM, Kelley WN, editors. Handbook of Experimental Pharmacology. New York: Springer; 1978. p. 347-64.
39. Kippen I et al. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974;33(4):313-7.
40. Perl-Treves D, Addadi L. A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization. Proc R Soc Lond B Biol Sci. 1988;235(1279):145-59.
41. Kaneko K,MaruM. Determination of urate crystal formation using flow cytometry and microareaX-ray diffractometry. Anal Biochem. 2000;281(1):9-14.
42. KamMet al. Antibodies against crystals. Faseb J. 1992;6(8):2608-13.
43. KamMet al. Specificity in the recognition of crystals by antibodies. J Mol Recognit. 1994;7(4):257-64.
44. Kanevets U et al. A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol. 2009;182(4):1912-8.
45. Terkeltaub R et al. Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. Arthritis Rheum. 1986;29(3):363-70.
46. Scanu A et al. High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther. 2010;12(1):11.
47. McGill NW, Hayes A, Dieppe PA. Morphological evidence for biological control of urate crystal formation in vivo and in vitro. Scand J Rheumatol. 1992;21(5):215-9.
48. Thiele RG. Role of ultrasound and other advanced imaging in the diagnosis and management of gout. Curr Rheumatol Rep. 2011;13(2):146-53.
49. Howard RGet al. Reproducibility ofmusculoskeletal ultrasound for determining monosodium urate deposition: Concordance between readers. Arthritis Care & Research. 2011;63(10):1456-62.
50. Hesse A et al. Uric acid dihydrate as urinary calculus component. Invest Urol. 1975;12(5):405-9.
51. Sakhaee K et al. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab. 1987;65(5):974-9.
52. Asplin Jr. Uric acid stones. Semin Nephrol. 1996;16(5):412-24.
53. Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62(3):971-9.
54. Pak CY et al. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60(2):757-61.
55. Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003;10(3):271-8.
56. Ettinger B et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386-9.
57. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489-96.
58. Pak CY et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest. 1977;59(3):426-31.
59. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056-8.
60. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4): 495-503.
61. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol. 2008;20(2):167-72.
62. Rimer JD et al. Crystal growth inhibitors for the prevention of Lcystine kidney stones through molecular design. Science. 2010;330(6002):337-41.